Aart Mookhoek |
At the 18th Congress of ECCO in Copenhagen in 2023, many exciting projects on artificial intelligence (AI) were presented. Most of these projects focused on the role of AI in endoscopy. As a pathologist, I asked myself the following question: What about the role of AI in the histological evaluation of IBD?
The pathologist plays an important role in establishing the diagnosis and in assessing therapy response. Given that in many parts of the world IBD prevalence is still rising and histological remission may soon become a treatment target, the workload for pathologists is expected to increase. Therefore, as it promises to guide and thereby reduce time spent on biopsy assessment, AI is an interesting tool for pathologists. Moreover, it may aid the mission of H-ECCO to “raise standards of IBD pathology reporting” by mitigating problems associated with inter-observer variability.
Literature on AI algorithms developed in the context of IBD histology is still limited. Moreover, to date implementation into daily clinical practice has not been reported. Here I offer a brief literature overview and discuss existing challenges.
In one of the first papers on AI in IBD histology, an algorithm was presented to quantify eosinophilic granulocytes [1]. Such an algorithm may contribute to research into the role of eosinophils in IBD. Several groups have now published algorithms that provide histological disease activity scores [2–4]. These algorithms, when completely validated, may find direct use in clinical practice as disease activity scores, such as the Nancy Index, are part of standard pathology reporting in some institutes. Another algorithm (paper under review at the time of writing) appears able to predict, based on histology alone, whether the endoscopic appearance matches Ulcerative Colitis or Crohn’s Disease [5].
The algorithms discussed above perform a single task with limited outcome options, whereas in clinical practice pathologists often perform multiple tasks with more possible outcomes. One example is the broad differential diagnosis that we encounter at first presentation. There are currently no published algorithms that address such a clinical situation. Another example is that of dysplasia detection in IBD. Although there is an algorithm for the different conventional types of dysplasia [6], the recently described non-conventional types of dysplasia in the context of IBD [7] would not be diagnosed by this algorithm.
The role of AI in IBD histology is currently limited to the research setting. As many pathology institutes have not completed the transition to digital pathology, this may not change for some time. However, the future of AI is both exciting and promising. Due to its multidisciplinary and collaborative nature, the ECCO Community is the ideal forum to discuss as well as to guide the future of AI in IBD histology.